Nevanac (nepafenac) remains a prescription NSAID eye drop used to reduce postoperative inflammation and, in diabetics, to lower the risk of macular edema after cataract surgery. Here’s the latest, distilled:
- Regulatory status: It is approved in major regions (EMA label materials from 2018 and UK/NHS appraisals show ongoing use for postoperative inflammation and macular edema prevention) [EMA: Nevanac EPAR; UK SmPC]. These sources indicate standard dosing regimens and safety profiles used in adults, with cautions for corneal health and potential adverse events [EMA: Nevanac EPAR][UK SmPC].
- Dosing and duration: Typical regimens involve multiple daily instillations starting around the time of cataract surgery; duration can extend up to 60 days when used to reduce macular edema risk, and shorter courses for general inflammation control, depending on regional labeling and clinician judgment [EMA EPAR; UK SmPC; NHS Wales/AWMSG assessments].
- Safety signals: The most common ocular adverse events include punctate keratitis, corneal epithelium defects, and rare allergic reactions; serious corneal events and epithelial breakdown can necessitate discontinuation and monitoring of corneal health [UK SmPC; EMA PIL/EMC extracts]. Contact lens wearers are advised to avoid during treatment due to benzalkonium chloride content, and hypersensitivity to nepafenac or NSAIDs is a contraindication [EMA EPAR; SmPC].
- Availability and access: Nevanac is typically available by prescription in many countries with national or regional formularies supporting its use for post-cataract inflammation and diabetic macular edema risk; local access may vary by country and updated guidance [EMA EPAR; NHS/Scotland appraisal notes].
If you’d like, I can pull the most current country-specific guidance (e.g., US, UK, EU, or your local health authority) and summarize any recent updates or changes to dosing, duration limits, or safety warnings. I can also provide a patient-friendly quick-reference dosing chart based on the latest official labels.
Would you like country-specific details or a concise dosing checklist for patients?
Citations: EMA Nevanac EPAR and associated product information; UK Medicines EMC/SmPC and NHS appraisal records.[2][3][4]
Sources
## Nevanac is an eye drop suspension that contains the active substance nepafenac (1 and 3 mg/ml). ## Nevanac is used in adults to prevent and treat the pain and inflammation that can occur after an operation to remove a cataract from the eye. Nevanac is also used to reduce the risk of macular oedema (swelling in the macula, the central part of the retina at the back of the eye) that can occur after cataract surgery in adult diabetes patients. The medicine can only be obtained with a...
www.ema.europa.euNevanac 1mg/ml eye drops suspension - Summary of Product Characteristics (SmPC) by Novartis Pharmaceuticals UK Ltd
www.medicines.org.ukimmediately discontinue use of NEVANAC and should be monitored closely for corneal health (see section 4.4). From post-marketing experience with NEVANAC 1 mg/ml eye drops, suspension, cases reporting corneal epithelium defect/disorder have been identified. Severity of these cases vary from non serious
www.ema.europa.euNHS Scotland. The advice is summarised as follows: ADVICE: following a full submission nepafenac (Nevanac®) is accepted for use within NHS Scotland. Indication under review: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. In the pivotal study which included diabetic patients who had undergone cataract surgery, nepafenac eye drops significantly reduced the incidence of macular oedema compared to vehicle. Overleaf is the detailed...
scottishmedicines.org.ukFind patient medical information for Nevanac (nepafenac) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
www.webmd.com